Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

39 recruitingLast updated: June 18, 2026

There are 39 actively recruiting diffuse large b-cell lymphoma (dlbcl) clinical trials across 28 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Chicago, Illinois, United States, Hangzhou, Zhejiang, China, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Diffuse Large B-Cell Lymphoma (DLBCL) Trials at a Glance

39 actively recruiting trials for diffuse large b-cell lymphoma (dlbcl) are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Chicago, Hangzhou, and Houston. Lead sponsors running diffuse large b-cell lymphoma (dlbcl) studies include Nurix Therapeutics, Inc., Beijing Tongren Hospital, and Ou Bai, MD/PHD.

Browse diffuse large b-cell lymphoma (dlbcl) trials by phase

Treatments under study

About Diffuse Large B-Cell Lymphoma (DLBCL) Clinical Trials

Looking for clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? There are currently 36 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Large B-Cell Lymphoma (DLBCL) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled155 locationsNCT06091865
Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 3

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled38 locationsNCT07188558
Recruiting
Phase 2

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled8 locationsNCT06765317
Recruiting
Phase 2

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University35 enrolled1 locationNCT07608978
Recruiting
Phase 2

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)Indolent B-Cell LymphomasIndolent B Cell Lymphoma
Azienda USL Reggio Emilia - IRCCS50 enrolled1 locationNCT06822829
Recruiting

Bio-CAR-T BS Study

Diffuse Large B-Cell Lymphoma (DLBCL)Acute Lymphoblastic Leukemia ALLPrimary Mediastinal Large B-cell Lymphoma (PMBCL)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia45 enrolled1 locationNCT05366569
Recruiting
Phase 2

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Diffuse Large B-Cell Lymphoma (DLBCL)
University Health Network, Toronto40 enrolled3 locationsNCT06050694
Recruiting
Phase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
TCRx Therapeutics Co.Ltd18 enrolled1 locationNCT07260812
Recruiting
Phase 2

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 3

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD200 enrolled1 locationNCT07493109
Recruiting
Phase 2

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD50 enrolled1 locationNCT07493148
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 2

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)+3 more
iOMEDICO AG2,950 enrolled1 locationNCT06043011